This is a correspondence from the authors responding to observations regarding the results of the STRIDE study, which investigated the effects of semaglutide in patients with type 2 diabetes and symptomatic Fontaine stage IIa peripheral artery disease.[1] The STRIDE trial was a randomized, placebo-controlled, double-blind, phase 3b trial that enrolled 972 type 2 diabetics and tested the addition of semaglutide 1 mg once weekly to prior treatment.[1] Semaglutide, as a glucagon-like peptide 1 (GLP-1) agonist, improved maximal walking distance in patients with symptomatic peripheral artery disease.[2] Other significant findings include a reduction in the need for salvage therapy (pharmacological or invasive) and all-cause mortality by more than half in patients treated with semaglutide (HR 0.46; 95% CI 0.24–0.85).[1] From this point of view, the effect of semaglutide was clinically more significant compared to treatment with cilostazol, which also has a wider spectrum of side effects and is contraindicated in heart failure.[1]